Indication
Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials.
Loading your page…
Loading your page…
Mucopolysaccharidosis II
Marketing Authorisation Holder: Takeda Pharmaceuticals International AG Ireland Branch
EMA Authorisation: 08/01/2007
INN: idursulfase
AI Drug & Interaction Analysis
Free account required
Ask Osler about Elaprase: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.